BioCryst To Raise Approximately $23.9 Million Through Sale Of Common Stock

21-Feb-2005

BioCryst Pharmaceuticals, Inc. announced that it has priced a registered direct offering for the sale of 4,350,000 shares of its common stock at a price of $5.50 per share to institutional investors. Leerink, Swann & Company served as placement agent for the transaction. The company expects this transaction to close on Friday, February 18, 2005.

The offered shares are registered pursuant to BioCryst's $60 million shelf registration statement that was declared effective by the Securities and Exchange Commission on January 5, 2004.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!